• Q3 FY26 positive operating cashflow of $1.7M driven by cash receipts of $14.5M
• Q3 new TCV sales of $11.7M including contract expansions and new contracts
• Selected as preferred provider for University Hospital Sussex NHS Foundation Trust's new EPR solution

Alcidion Group Limited (ASX:ALC) has released its Appendix 4C and Quarterly Activities Report for the quarter ended 31 March 2026 (Q3 FY26). The company achieved positive operating cashflow of $1.7M driven by cash receipts of $14.5M. Q3 new TCV sales were $11.7M, including contract expansions for Miya Emergency (Miya ED) with Hywel Dda and South Tees, a new contract for Remote Patient Monitoring (Virtual Care) with Gold Coast Health, and several existing contract renewals for Patientrack and PCS. Alcidion was also selected as the preferred provider for University Hospital Sussex NHS Foundation Trust's (UHSussex) new EPR solution, with the contract expected to be finalized in May 2026. As of 31 March 2026, Alcidion has FY26 contracted (sold & renewal) revenue of $43.8M, excluding the UHSussex contract. The company reconfirmed its FY26 financial guidance of revenue exceeding $50.0M with EBITDA in excess of $5.0M, and operating cashflow to remain positive in-line with FY25 operating cashflow of $5.8M.

Revenue expected to exceed $50.0M with EBITDA in excess of $5.0M for FY26. Operating cashflow to remain positive and in-line with FY25 operating cashflow of $5.8M.

Alcidion has FY26 contracted (sold and renewal) revenue of $43.8M as of 31 March 2026, up 9% on the prior corresponding period. This does not include any revenue contribution from the University Hospitals Sussex EPR contract or other potential new contract wins which may occur over the final quarter of the financial year.